Peptide Drug Challenges through Pre-ANDA Processes & Case Studies (6of39) Complex Generics 2018

Eric S. Pang from the Office of Generic Drugs shares an introduction to peptide drug products to include regulatory pathways and guidance on generic synthetic peptides referencing RLD of rDNA origin. He provides case studies on API characterization, alternative formulation, and immunogenicity assessment.
-----------------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cd...
CDER SBIA 2018 Playlist: • 2018 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cd...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...
Email: [e-mail]
Phone: [phone] I [phone]